Spark Therapeutics to Participate in Multiple Conferences in October
October 03 2017 - 7:30AM
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy
company dedicated to challenging the inevitability of genetic
disease, today announced that company management will present at
the following October conferences.
European Society of Gene & Cell Therapy (ESGCT)
Congress, at the Berlin Congress Center in
Berlin
- Federico Mingozzi, Ph.D., chief scientific officer, will
present on “SPK-9001 – an Adeno-Associated Virus Mediated Gene
Transfer for Hemophilia B” on Thursday, Oct. 19, at 2:10 p.m.
CET
Additionally, company management will present at the following
investor conferences:
- Chardan Gene Therapy Conference on Tuesday, Oct. 10, at 11:40
a.m. EDT, at the Westin Grand Central in New York
- Jefferies Gene Technology Investor Summit on Thursday, Oct. 12,
at 9:00 a.m. EDT, at the Westin Grand Central in New York
About Spark Therapeutics Spark
Therapeutics, a fully integrated company, strives to challenge the
inevitability of genetic disease by discovering, developing and
delivering gene therapies that address inherited retinal
diseases (IRDs), neurodegenerative diseases, as well as diseases
that can be addressed by targeting the liver, such as
hemophilia. Spark Therapeutics has ongoing clinical
trials investigating gene therapies in hemophilia A and
B. SPK-8011 is in an ongoing, dose-escalation Phase 1/2
clinical trial as a potential one-time therapy for hemophilia A.
The company retains full global commercialization rights to
SPK-8011. SPK-9001 is in a Phase 1/2 clinical trial for
hemophilia B and is being developed in collaboration with Pfizer.
It has received both breakthrough therapy and orphan product
designations from the Food and Drug Administration (FDA),
and access to the PRIority MEdicines (PRIME) Program from the
European Medicines Agency (EMA). Our most advanced investigational
candidate, with proposed trade name LUXTURNA™ (voretigene
neparvovec), is currently under Priority Review with FDA for
the treatment of patients with vision loss due to confirmed
biallelic RPE65-mediated IRD and has been designated as a drug
for a rare pediatric disease. The Marketing Authorization
Application for LUXTURNA has been validated by EMA for the
treatment of patients with vision loss due to Leber congenital
amaurosis (LCA) or retinitis pigmentosa (RP) IRDs caused by
confirmed biallelic RPE65 mutations. LUXTURNA has received
breakthrough therapy and orphan product designations
from FDA and orphan product designations from EMA. The
pipeline also includes SPK-7001 in an ongoing Phase 1/2
clinical trial for choroideremia. For more information, visit
www.sparktx.com, and follow us on Twitter and LinkedIn.
Investor
Contact: |
|
Media
Contact: |
Ryan Asay |
|
Monique da Silva |
Ryan.asay@sparktx.com |
|
Monique.dasilva@sparktx.com |
(215) 239-6424 |
|
(215) 282-7470 |
Onconetix (NASDAQ:ONCE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Onconetix (NASDAQ:ONCE)
Historical Stock Chart
From Sep 2023 to Sep 2024